xRead - Nasal Obstruction (September 2024) Full Articles

20426984, 0, Downloaded from https://onlinelibrary.wiley.com/doi/10.1002/alr.23262, Wiley Online Library on [02/01/2024]. See the Terms and Conditions (https://onlinelibrary.wiley.com/terms-and-conditions) on Wiley Online Library for rules of use; OA articles are governed by the applicable Creative Commons License

117

ICAR SINONASAL TUMORS

TABLE XIV.1 Evidence surrounding IMRT in treatment of sinonasal tumors.

Clinical endpoints 1. 3-year LC 2. 3-year OS

Study

Year LOE Study design Study groups

Conclusion

Zhang et al. 474

1. LC68% 2. OS64% 3. LC and OS were significantly higher after CIRT than PBT or IMRT 4. No significant difference between PRT and IMRT for OS and LC was observed IMRT has contributed to the substantial improvement in clinical outcomes of these patients, both in terms of primary tumor control and avoidance of toxicities 1. LRC 0.64 (95% CI: 0.57–0.72) 2. DFS 0.5 (95% CI: 0.38–0.67) 3. OS 0.48 (95% CI: 0.38–0.60) 4. PBT showed significantly higher DFS at 5-year and LRC at longest follow-up compared to IMRT 10.4%( n = 12) of patients had postoperative complications, and 21.0%( n = 22) had high-grade (grade 3–5) RT toxicity 1. Noncompliance was associated withLRF 2. 5-year OS was 56% in patients treated with curative intent 3. Combined treatment strategy showed reduced LRF 1. OS 33 months 2. Pretherapeutic GTV was prognostic (cutoff 75 cm 3 ) Induction chemotherapy followed by radiation gives the best outcomes 1. The locoregional recurrence rate was 18% following IMRT versus 31%in the two/three-dimensional conventional RT group ( p = 0.09) 2. IMRT was associated with a lower inner ear toxicity rate (8% vs. 20%, respectively; p = 0.045) 1. LC67% 2. PFS59% 3. OS74%

44 cohorts comparing 2282 patients treated with CIRT, PBT or IMRT (IMRT, n = 772)

2020 2

Systematic

reviewand meta analysis

Liang et al. 475

2018 2

Systematic review

20 studies evaluating IMRT for SNM ( n = 1274)

Clinical

outcomes

Patel et al. 458

1. Longest

41 studies evaluating SNM patients undergoing either particle or photon radiotherapy ( n = 1472; IMRT

2014 2

Systematic

follow-up LRC 2. 5-year DFS 3. 5-year OS

reviewand meta analysis

therapy n = 187 for DFSand n = 212 for OS)

Patel et al. 476

2020 3

Retrospective cohort

SNM at a single

Toxicity

institution ( n = 60)

1. Guideline

Filtenborg et al. 465

SNMacross

2021

4

Retrospective database review

compliance

multi-institutional national database ( n = 331)

2. 5-year OS

(DAHANCA)

Klymenko et al. 477

2021

4

Retrospective case series

SNM at a single

OS

institution ( n = 53)

Korra et al. 478

2021

4

Retrospective case series

ONB at a single

1. 5-year OS 2. RFS

institution ( n = 13)

Laskar et al. 479

2021

4

Retrospective case series

SNM at a single

1. 5-year LC 2. 5-year PFS 3. 5-year OS

institution ( n = 214)

Owinet al. 480

1. LRC 2. Tox

2021

4

Retrospective case series

SNM at a single

institution ( n = 104; IMRT n = 88, 3DCRT n = 13;NRT n = 3)

Slevin et al. 481

2021

4

Retrospective case series

SNM across four

1. 5-year PFS 2. 5-year OS

1. PFS24% 2. OS30%

institutions ( n = 56)

(Continues)